Business
Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Phase 1b/2 clinical trial of ALRN-6924 as a myelopreservation agent for the protection against chemotherapy-induced toxicity in small cell lung cancer started
About this update from Rein Therapeutics, Inc.
[{"type":"text","content":"Phase 1b/2 clinical trial of ALRN-6924 as a myelopreservation agent for the protection against chemotherapy-induced toxicity in small cell lung cancer started dosing patients September 2019; interim data suggests reduction in severe anemia and thrombocytopenia; encouraging results led to the plan to test second dosing schedule to assess if effects can be extended to reduction in severe neutropeniaDue to uncertainty and enrollment delays associated with the coronavirus pandemic, efforts are now focused solely on the development of ALRN-6924 as a myelopreservation agent; the company is planning to implement measures to reduce operating expenses to extend its cash runway to first quarter 2021\n WATERTOWN, Mass., March 30, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019. “We continue to advance our lead clinical program evaluating ALRN-6924 as an agent that protects patients with p53-mutant cancers against chemotherapy-induced toxicity, which is a novel treatment concept known as ‘myelopreservation’. The dose-optimization Phase 1b portion of the Phase 1b/2 clinical trial started dosing small cell lung cancer (SCLC) patients in September 2019. After observing encouraging interim data from the initial cohorts showing a protective effect against severe anemia and thrombocytopenia, we decided to test a second dosing schedule to assess whether the myelopreservation effect may also be extended to include severe neutropenia. However, enrollment has recently been slowed by the coronavirus pandemic. Subject to potential further delays from the global impact of this pandemic, we plan to present proof of concept data from the Phase 1b portion of the trial in the fourth quarter of 2020,” said Dr. Manuel Aivado, President and CEO of Aileron Therapeutics. “In light of our cash resources and the uncertainties associated with the coronavirus pandemic, we have decided to focus our efforts solely on the development of ALRN-6924 as a myelopreservation agent and plan to reduce our operating expenses in order to extend our cash runway from the fourth quarter of 2020 to the first quarter of 2021.” ALRN-6924 as a myelopreservation agent In Septembe...